Helen Rizos

Professor

  • 3279 Citations
  • 35 h-Index
1989 …2022
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Helen Rizos is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Melanoma Medicine & Life Sciences
Tumor Suppressor Protein p14ARF Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Tumors Chemical Compounds
Melanocytes Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2022

Centre of Research Excellence in Melanoma: Person, tumour and system-focussed knowledge to drive better outcomes in melanoma

Braithwaite, J., Mann, G. J., Cust, A. E., Scolyer, R. A., Kelly, J., Morton, R. L., Spillane, A. J., Saw, R., Henderson, M., Yang, J. Y. H., Hong, A., Tran, A., Gyorki, D., Milne, D., Long, G. V., Rizos, H., Kasparian, N., Fernández-Peñas, P. & Guitera, P.

1/01/1831/12/22

Project: Other

Research Outputs 1989 2019

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy

Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Immunotherapy
Melanoma
Cytokines
Confidence Intervals
Therapeutics

Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy

Gide, T. N., Quek, C., Menzies, A. M., Tasker, A. T., Shang, P., Holst, J., Madore, J., Lim, S. Y., Velickovic, R., Wongchenko, M., Yan, Y., Lo, S., Carlino, M. S., Guminski, A., Saw, R. P. M., Pang, A., McGuire, H. M., Palendira, U., Thompson, J. F., Rizos, H. & 5 othersSilva, I. P. D., Batten, M., Scolyer, R. A., Long, G. V. & Wilmott, J. S., 11 Feb 2019, In : Cancer Cell. 35, 2, p. 238-255.e6 24 p.

Research output: Contribution to journalArticleResearchpeer-review

T-Lymphocytes
Immunotherapy
Population
Neoplasms
Therapeutics

Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma

da Silva, I. P., Wang, K. Y. X., Wilmott, J. S., Holst, J., Carlino, M. S., Park, J. J., Quek, C., Wongchenko, M., Yan, Y., Mann, G., Johnson, D. B., McQuade, J. L., Rai, R., Kefford, R. F., Rizos, H., Scolyer, R. A., Yang, J. Y. H., Long, G. V. & Menzies, A. M., 15 Feb 2019, In : Clinical Cancer Research. 25, 4, p. 1272-1279 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Immunotherapy
Melanoma
MAP Kinase Signaling System
Atlases
Dual Specificity Phosphatase 6

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients

Lee, H., Quek, C., Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S. Y., Nur Gide, T., Shang, P., Attrill, G. H., Madore, J., Edwards, J., Carlino, M. S., Guminski, A., Saw, R. P. M., Thompson, J. F., Ferguson, P. M., Palendira, U., Menzies, A. M., Long, G. V. & 2 othersScolyer, R. A. & Wilmott, J. S., Feb 2019, In : OncoImmunology. 8, 2, p. 1-10 10 p., e1537581.

Research output: Contribution to journalArticleResearchpeer-review

Natural Killer Cells
Melanoma
Major Histocompatibility Complex
Therapeutics
Neoplasms

Label-free fluorescent poly(amidoamine) dendrimer for traceable and controlled drug delivery

Wang, G., Fu, L., Walker, A., Chen, X., Lovejoy, D. B., Hao, M., Lee, A., Chung, R., Rizos, H., Irvine, M., Zheng, M., Liu, X., Lu, Y. & Shi, B., 13 May 2019, In : Biomacromolecules. 20, 5, p. 2148-2158 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Controlled drug delivery
Dendrimers
Cytotoxicity
Doxorubicin
Labels

Prizes